2010

Expansion of manufacturing sites

Another expansion of manufacturing sites too place in the form of a 1,026 square meters shop for tablets and capsules, equipped with machines for granulation, dry-mixing, tableting and coating.

Tchaikapharma surpasses new EU standards

On Feb. 1, the Bulgarian Drug Agency issued a GMP Certificate for compliance with the EU requirements, in accordance with the Law on Medicinal Products in Human Medicine as amended. By that time the agency had been making annual inspections for compliance with the national manufacturing requirements. Still the standards we work with surpass the requirements of local legislation and adhere to much higher in-house criteria.


New marketing contracts

In 2010, Tchaikapharma High Quality Medicines, Inc. was granted marketing authorizations for 15 medicines:Alonet (amisulpride), Betablockade (metoprolol succinate), Cefuroxime-Tchaikapharma (cefuroxime), Kefadim (ceftazidime), Lifurox (cefuroxime), Bisor (bisoprolol fumarate), Cardifriend (ramipril), Climox  (amoxicillin / clavulanic acid),  Fosanat (alendronate), PlaquEx (clopidogrel), Pravastatin-Tchaikapharma( pravastatin), ParaCeta (paracetamol), Tobanex (topiramate), Venlafectin (venlafaxin) and Ibufen (ibuprofen).


Expansive product portfolio

In 2010 Tchaikapharma High Quality Medicines, Inc. has 69 registered medicines, covering all major therapeutic areas: cardiovascular system, central nervous system, digestive system, muscle and skeletal system, bacterial infections, coagulation and fibrinolysis, oncology, endocrine system, respiratory system, urogenital system, analgetics and antipyretics. The portfolio also includes a wide range of vitamins and food additives. The two plants annually package 280 million tablets.


Tchaikapharma High Quality Medicines continues to develop as a new large-scale manufacturing project in Plovdiv is underway.